<?xml version="1.0" encoding="UTF-8" standalone="yes"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="community-medicine" lang="en"> <front> <journal-meta> <journal-id journal-id-type="publisher">JOHS</journal-id> <journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id> <journal-title-group> <journal-title>Journal of HealthCare Sciences</journal-title> <abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title> </journal-title-group> <issn pub-type="ppub">2231-2196</issn> <issn pub-type="opub">0975-5241</issn> <publisher> <publisher-name>Radiance Research Academy</publisher-name> </publisher> </journal-meta> <article-meta> <article-id pub-id-type="publisher-id">132</article-id> <article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2022.21210</article-id> <article-id pub-id-type="doi-url"/> <article-categories> <subj-group subj-group-type="heading"> <subject>Community Medicine</subject> </subj-group> </article-categories> <title-group> <article-title>Prevention, Evaluation, and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis </article-title> </title-group> <contrib-group> <contrib contrib-type="author"> <name> <surname>Alalwani</surname> <given-names>Osamh</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>Baarmah</surname> <given-names>Hala</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>AlOlaiwi</surname> <given-names>Lubna</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>Almansour</surname> <given-names>Sara</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>AlFaran</surname> <given-names>Kifayah</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>Alzahrani</surname> <given-names>Abdullah</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>Alqbbani</surname> <given-names>Saad</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>Albarqi</surname> <given-names>Rakan</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>Alghamdi</surname> <given-names>Nawaf</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>Altuwaijri</surname> <given-names>Abdulrahman</given-names> </name> </contrib> <contrib contrib-type="author"> <name> <surname>AlAli</surname> <given-names>Ahmad</given-names> </name> </contrib> </contrib-group> <pub-date pub-type="ppub"> <day>30</day> <month>11</month> <year>-0001</year> </pub-date> <volume>2</volume> <issue>12</issue> <fpage>568</fpage> <lpage>575</lpage> <permissions> <copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement> <copyright-year>2009</copyright-year> <license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"> <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p> </license> </permissions> <abstract> <p>Oral mucositis is a frequent adverse effect of cancer treatment that includes radiotherapy (RT) and chemotherapy (CT). It is related to worse outcomes because of pain, nutritional problems, effects on quality of life, changes in cancer treatment, the risk of infection, and financial costs. It affects 20% to 80% of people receiving chemotherapy, and almost all patients receive head and neck radiation therapy. This review presents the current understanding and discusses evidence-based clinical management strategies for oral mucositis. The current model of mucositis pathogenesis is comprised of five broad stages. The two widely used grading systems for routine clinical care and research on mucositis are the WHO (World Health Organization) and Oral Mucositis Scale and the National Cancer Institute__ampersandsign#39;s Common Toxicity Criteria (NCI-CTC). The effective use of assessment scales, nonpharmacologic treatment modalities such as good professional oral hygiene, cryotherapy, and photobiomodulation, and pharmacologic therapies such as KGF-1 (palifermin) and benzydamine-containing mouthwash are important for mucositis prevention, and topical morphine is effective for the treatment of mucositis induced by radiotherapy or chemotherapy. Mucoadhesive hydrogel and anti-inflammatory medications such as celecoxib, misoprostol, and rebamipide are reported to be effective for radiation-induced mucositis. However, additional experimental studies are required to confirm the evidence. </p> </abstract> <kwd-group> <kwd>oral mucositis</kwd> <kwd> cancer</kwd> <kwd> treatment</kwd> <kwd> radiotherapy</kwd> <kwd> chemotherapy</kwd> </kwd-group> </article-meta> </front> </article>